Retrospective analysis of large‑scale research screening of construction workers for the early diagnosis of mesothelioma
- Authors:
- Tomoko Hirohashi
- Kiyoko Igarashi
- Masaaki Abe
- Masahiro Maeda
- Okio Hino
View Affiliations
Affiliations: Department of Pathology and Oncology, School of Medicine, Juntendo University, Bunkyo-Ku, Tokyo 113‑8421, Japan, Byotai‑seiri Laboratory, Itabashi-Ku, Tokyo 173‑0025, Japan, Immuno‑Biological Laboratories, Co., Ltd., Fujioka-shi, Gunma 375‑0005, Japan
- Published online on: October 2, 2013 https://doi.org/10.3892/mco.2013.197
-
Pages:
26-30
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Abstract
The early diagnosis of mesothelioma, an aggressive malignant tumor, is considered to be important for prognosis. X‑ray is commonly used for the assessment of a mass in a population exhibiting a risk factor. However, there are currently no available studies indicating that such an assessment may be used to achieve early diagnosis and improve the patient's outcome. We previously reported that N‑ERC/mesothelin may be a useful blood tumor marker for mesothelioma. In order to investigate whether this tumor marker is useful for early diagnosis in a mass examination, in 2007 we initiated a 5‑year large‑scale screening of construction workers with a risk of asbestos exposure in Japan. Blood samples were collected annually and N‑ERC/mesothelin levels were determined. Based on the results of those findings, along with medical history and related data, we screened the participants to identify a high‑risk population. As a result, 62 subjects were identified among ~40,000 participants as the high‑risk population. Two of these 62 participants subsequently developed mesothelioma, although the remaining participants have not yet developed mesothelioma. In conclusion, N‑ERC/mesothelin may be useful as a blood tumor marker in the early diagnosis of mesothelioma in a mass examination. A future prospective study to confirm the findings of this research screening is currently under planning.
View References
|
1.
|
Gemba K, Fujimoto N, Kato K, Aoe K,
Takeshima Y, Inai K and Kishimoto T: National survey of
mesothelioma and asbestos exposure in Japan. Cancer Sci.
103:483–490. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Nakano T: Current therapies for malignant
pleural mesothelioma. Environ Health Prev Med. 13:75–83. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Robinson BW, Musk AW and Lake RA:
Mesothelioma. Lancet. 366:397–408. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Reid A, de Klerk N, Ambrosini G, Olsen N,
Pang SC and Musk AW: The additional risk of mesothelioma in former
workers and residents of Wittenoom with benign pleural disease or
asbestosis. Occup Environ Med. 62:665–669. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Sandén A and Järvholm B: A study of
possible predictors of mesothelioma in shipyard workers exposed to
asbestos. J Occup Med. 33:770–773. 1991.PubMed/NCBI
|
|
6.
|
Hino O, Kobayashi E, Nishizawa M, et al:
Renal carcinogenesis in the Eker rat. J Cancer Res Clin Oncol.
121:602–605. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Yamashita Y, Yokoyama M, Kobayashi E,
Takai S and Hino O: Mapping and determination of the cDNA sequence
of the Erc gene preferentially expressed in renal cell carcinoma in
the Tsc2 gene mutant (Eker) rat model. Biochem Biophys Res Commun.
275:134–140. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Hino O: Multistep renal carcinogenesis in
the Eker (Tsc 2 gene mutant) rat model. Curr Mol Med. 4:807–811.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Hassan R, Bera T and Pastan I: Mesothelin:
a new target for immunotherapy. Clin Cancer Res. 10:3937–3942.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Shiomi K, Miyamoto H, Segawa T, et al:
Novel ELISA system for detection of N-ERC/mesothelin in the sera of
mesothelioma patients. Cancer Sci. 97:928–932. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Shiomi K, Hagiwara Y, Sonoue K, et al:
Sensitive and specific new enzyme-linked immunosorbent assay for
N-ERC/mesothelin increases its potential as a useful serum tumor
marker for mesothelioma. Clin Cancer Res. 14:1431–1437. 2008.
View Article : Google Scholar
|
|
12.
|
Imashimizu K, Shiomi K, Maeda M, Aoki N,
Igarashi K, Suzuki F, Koizumi M, Suzuki K and Hino O: Feasibility
of large-scale screening using N-ERC/mesothelin levels in the blood
for the early diagnosis of mesothelioma. Exp Ther Med. 2:409–411.
2011.PubMed/NCBI
|
|
13.
|
Shiomi K, Shiomi S, Ishinaga Y, et al:
Impact of renal failure on the tumor markers of mesothelioma,
N-ERC/mesothelin and osteopontin. Anticancer Res. 31:1427–1430.
2011.PubMed/NCBI
|
